

## News Release

August 1, 2017  
Galderma KK  
Maruho Co., Ltd.

### **Maruho Succeeds Manufacturing and Marketing Approval for Acne Vulgaris Treatment “Epiduo® Gel”**

Osaka and Tokyo (Japan), August 1, 2017 – Maruho Co., Ltd. (“Maruho”, Head Office: Osaka, Japan, President and CEO: Koichi Takagi) and Galderma KK (Head Office: Tokyo, Japan, Representative Director: Leslaw Rudy) announce today that from August 1, 2017, Maruho will succeed the marketing and manufacturing approval in Japan from Galderma KK for acne vulgaris treatment “Epiduo® Gel” (hereinafter referred to as “Epiduo”).

Epiduo is a topical formulation of a fixed-dose drug combination containing adapalene and benzoyl peroxide developed by Galderma Pharma S.A. (“Galderma SA”, Headquarters: Lausanne, Switzerland, CEO: Stuart Raetzman). Since its first marketing authorization in Europe in 2007, Epiduo has now been approved in 78 countries and areas around the world.

Maruho and Galderma SA agreed to enter into a comprehensive set of agreements to form a strategic alliance focused on the development and commercialization of Galderma SA’s prescription drugs for dermatology in Japan. Maruho has appropriately provided and collected medical information as the distributor of Epiduo in Japan. From August 1, 2017, Maruho will appropriately provide and collect information as the manufacturer and distributor of Epiduo in Japan and will ensure a stable supply of this product.

As a pharmaceutical company specializing in dermatology, Maruho hopes to further contribute to patients suffering from acne vulgaris through the succession of marketing and manufacturing approval for Epiduo in Japan.

**About Galderma**

Galderma, Nestlé Skin Health's medical solutions business, was created in 1981 and is now present in over 100 countries with an extensive product portfolio to treat a range of dermatological conditions. The company partners with health care professionals around the world to meet the skin health needs of people throughout their lifetime. Galderma is a leader in research and development of scientifically-defined and medically-proven solutions for the skin, hair and nails.

For more information, please visit [www.galderma.com](http://www.galderma.com)

**About Maruho**

Maruho Co., Ltd. has its headquarters in Osaka and leads Japan in research and development, manufacturing and commercialization of dermatological products. Founded in 1915, Maruho has 1,398 employees (as of the end of September 2016), and net sales were approximately 70.1 billion yen in its 2016 fiscal year. Pursuing its long-term corporate vision of "Excellence in Dermatology," Maruho is striving to improve the health and quality of life of people all over the world.

For more information, please visit [www.maruho.co.jp/english](http://www.maruho.co.jp/english)

**Contact Information:**

Galderma KK

Kimimoto Sugino

Tel:+81-(0)3-6628-6616 Fax:+81-(0)3-6628-6659

Email: [award.japan@galderma.com](mailto:award.japan@galderma.com)

Maruho Co., Ltd.

Corporate Communications Dept.

Roger Matthews

Tel: +81-(0)6-6371-8831 Fax: +81-(0)6-6376-8679

Email: [kouhou@mii.maruho.co.jp](mailto:kouhou@mii.maruho.co.jp)